Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Greene NZ, Wiley JL, Yu Z, Clowers BH, Craft RM.

Psychopharmacology (Berl). 2018 Sep 20. doi: 10.1007/s00213-018-5036-z. [Epub ahead of print]

PMID:
30238130
2.

Diarylureas Containing 5-Membered Heterocycles as CB1 Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation.

Nguyen T, Gamage TF, Decker AM, German N, Langston TL, Farquhar CE, Kenakin TP, Wiley JL, Thomas BF, Zhang Y.

ACS Chem Neurosci. 2018 Sep 20. doi: 10.1021/acschemneuro.8b00396. [Epub ahead of print]

PMID:
30188693
3.

Medical cannabis legalization and state-level prevalence of serious mental illness in the National Survey on Drug Use and Health (NSDUH) 2008-2015.

Dutra LM, Parish WJ, Gourdet CK, Wylie SA, Wiley JL.

Int Rev Psychiatry. 2018 Jun;30(3):203-215. doi: 10.1080/09540261.2018.1467385. Epub 2018 Jul 16.

PMID:
30010452
4.

A Conceptual Framework for Understanding Multiple Tobacco Product Use and the Impact of Regulatory Action.

Pacek LR, Wiley JL, Joseph McClernon F.

Nicotine Tob Res. 2018 Jun 20. doi: 10.1093/ntr/nty129. [Epub ahead of print]

PMID:
29931176
5.

Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats.

Barrus DG, Lefever TW, Wiley JL.

Neuropharmacology. 2018 Jul 15;137:133-140. doi: 10.1016/j.neuropharm.2018.04.018. Epub 2018 May 3.

PMID:
29758385
6.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

PMID:
29549157
7.

Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF.

Neuropharmacology. 2018 May 15;134(Pt A):73-81. doi: 10.1016/j.neuropharm.2017.10.041. Epub 2017 Nov 4.

PMID:
29113898
8.

Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats.

Marusich JA, Darna M, Wilson AG, Denehy ED, Ebben A, Deaciuc AG, Dwoskin LP, Bardo MT, Lefever TW, Wiley JL, Reissig CJ, Jackson KJ.

Eur J Pharmacol. 2017 Nov 5;814:196-206. doi: 10.1016/j.ejphar.2017.08.029. Epub 2017 Aug 26.

PMID:
28844873
9.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

PMID:
28834241
10.

In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

11.

The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL.

Neuropharmacology. 2017 Oct;125:365-375. doi: 10.1016/j.neuropharm.2017.08.008. Epub 2017 Aug 10.

12.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.

Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2017 Sep 14;60(17):7410-7424. doi: 10.1021/acs.jmedchem.7b00707. Epub 2017 Aug 18.

13.

Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.

Owens RA, Mustafa MA, Ignatowska-Jankowska BM, Damaj MI, Beardsley PM, Wiley JL, Niphakis MJ, Cravatt BF, Lichtman AH.

Neuropharmacology. 2017 Oct;125:80-86. doi: 10.1016/j.neuropharm.2017.06.032. Epub 2017 Jun 30.

14.

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.

Subst Abuse. 2017 Apr 7;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

15.

Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Britch SC, Wiley JL, Yu Z, Clowers BH, Craft RM.

Drug Alcohol Depend. 2017 Jun 1;175:187-197. doi: 10.1016/j.drugalcdep.2017.01.046. Epub 2017 Apr 15.

16.

Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.

17.

Youth use of electronic vapor products and blunts for administering cannabis.

Eggers ME, Lee YO, Jackson K, Wiley JL, Porter L, Nonnemaker JM.

Addict Behav. 2017 Jul;70:79-82. doi: 10.1016/j.addbeh.2017.02.020. Epub 2017 Feb 10.

PMID:
28214740
18.

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Lefever TW, Lee YO, Kovach AL, Silinski MA, Marusich JA, Thomas BF, Wiley JL.

Drug Alcohol Depend. 2017 Mar 1;172:80-87. doi: 10.1016/j.drugalcdep.2016.12.004. Epub 2017 Jan 18.

19.

Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Wiley JL, Lefever TW, Marusich JA, Craft RM.

Drug Alcohol Depend. 2017 Mar 1;172:51-59. doi: 10.1016/j.drugalcdep.2016.11.035. Epub 2017 Jan 11.

20.

Tasty THC: Promises and Challenges of Cannabis Edibles.

Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL.

Methods Rep RTI Press. 2016 Nov;2016. doi: 10.3768/rtipress.2016.op.0035.1611.

21.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

22.

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, Zhang Y.

Med Res Rev. 2017 May;37(3):441-474. doi: 10.1002/med.21418. Epub 2016 Nov 23. Review.

23.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

24.

Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.

Wiley JL, Marusich JA, Thomas BF.

Curr Top Behav Neurosci. 2017;32:231-248. doi: 10.1007/7854_2016_17. Review.

PMID:
27753007
25.

Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats.

Craft RM, Haas AE, Wiley JL, Yu Z, Clowers BH.

Pharmacol Biochem Behav. 2017 Jan;152:36-43. doi: 10.1016/j.pbb.2016.09.006. Epub 2016 Sep 24.

26.

Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF.

Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.

27.

Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and FAAH(+/+) mice.

Wiley JL, Lefever TW, Pulley NS, Marusich JA, Cravatt BF, Lichtman AH.

Behav Pharmacol. 2016 Aug;27(5):479-84. doi: 10.1097/FBP.0000000000000228.

28.

Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.

Owens RA, Ignatowska-Jankowska B, Mustafa M, Beardsley PM, Wiley JL, Jali A, Selley DE, Niphakis MJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2016 Aug;358(2):306-14. doi: 10.1124/jpet.115.229492. Epub 2016 Jun 15.

29.

Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.

Wiley JL, Owens RA, Lichtman AH.

Curr Top Behav Neurosci. 2018;39:153-173. doi: 10.1007/7854_2016_24.

PMID:
27278640
30.

Pharmacological effects of methamphetamine and alpha-PVP vapor and injection.

Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL.

Neurotoxicology. 2016 Jul;55:83-91. doi: 10.1016/j.neuro.2016.05.015. Epub 2016 May 26.

31.

The impact of gonadal hormones on cannabinoid dependence.

Marusich JA, Craft RM, Lefever TW, Wiley JL.

Exp Clin Psychopharmacol. 2015 Aug;23(4):206-16. doi: 10.1037/pha0000027.

32.

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF.

J Pharmacol Exp Ther. 2015 Sep;354(3):328-39. doi: 10.1124/jpet.115.225326. Epub 2015 Jun 23.

33.

A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.

Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M, Zanato C, Greig IR, Lichtman AH, Ross RA.

Neuropsychopharmacology. 2015 Dec;40(13):2948-59. doi: 10.1038/npp.2015.148. Epub 2015 Jun 8.

34.

Gonadal hormones do not alter the development of antinociceptive tolerance to delta-9-tetrahydrocannabinol in adult rats.

Wakley AA, Wiley JL, Craft RM.

Pharmacol Biochem Behav. 2015 Jun;133:111-21. doi: 10.1016/j.pbb.2015.03.021. Epub 2015 Apr 8.

35.

Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.

Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y.

Bioorg Med Chem. 2015 May 1;23(9):2195-2203. doi: 10.1016/j.bmc.2015.02.058. Epub 2015 Mar 7.

36.

Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.

Ignatowska-Jankowska B, Wilkerson JL, Mustafa M, Abdullah R, Niphakis M, Wiley JL, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 May;353(2):424-32. doi: 10.1124/jpet.114.222315. Epub 2015 Mar 11.

37.

Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.

Walentiny DM, Vann RE, Wiley JL.

Neuropharmacology. 2015 Jun;93:237-42. doi: 10.1016/j.neuropharm.2015.02.004. Epub 2015 Feb 16.

38.

Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Wiebelhaus JM, Grim TW, Owens RA, Lazenka MF, Sim-Selley LJ, Abdullah RA, Niphakis MJ, Vann RE, Cravatt BF, Wiley JL, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2015 Feb;352(2):195-207. doi: 10.1124/jpet.114.218677. Epub 2014 Nov 14.

39.

Baths salts, spice, and related designer drugs: the science behind the headlines.

Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL.

J Neurosci. 2014 Nov 12;34(46):15150-8. doi: 10.1523/JNEUROSCI.3223-14.2014. Review.

40.

Determination of behaviorally effective tobacco constituent doses in rats.

Wiley JL, Marusich JA, Thomas BF, Jackson KJ.

Nicotine Tob Res. 2015 Mar;17(3):368-71. doi: 10.1093/ntr/ntu194. Epub 2014 Sep 30.

41.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).

German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2014 Sep 25;57(18):7758-69. doi: 10.1021/jm501042u. Epub 2014 Sep 4.

42.

Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat.

Wakley AA, Wiley JL, Craft RM.

Drug Alcohol Depend. 2014 Oct 1;143:22-8. doi: 10.1016/j.drugalcdep.2014.07.029. Epub 2014 Aug 2.

43.

Sex differences in Δ(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats.

Wiley JL, Burston JJ.

Neurosci Lett. 2014 Jul 25;576:51-5. doi: 10.1016/j.neulet.2014.05.057. Epub 2014 Jun 5.

44.

Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.

Wiley JL, Lefever TW, Cortes RA, Marusich JA.

Pharmacol Biochem Behav. 2014 Sep;124:123-8. doi: 10.1016/j.pbb.2014.05.016. Epub 2014 Jun 2.

45.

Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.

Wiley JL, Walentiny DM, Wright MJ Jr, Beardsley PM, Burston JJ, Poklis JL, Lichtman AH, Vann RE.

Eur J Pharmacol. 2014 Aug 15;737:97-105. doi: 10.1016/j.ejphar.2014.05.013. Epub 2014 May 22.

46.

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.

Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA, Pertwee RG, Lichtman AH.

Behav Pharmacol. 2014 Apr;25(2):182-5. doi: 10.1097/FBP.0000000000000027.

47.

Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).

Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH.

Neuropharmacology. 2014 Dec;87:206-13. doi: 10.1016/j.neuropharm.2014.02.016. Epub 2014 Mar 2.

48.

Evaluation of sex differences in cannabinoid dependence.

Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL.

Drug Alcohol Depend. 2014 Apr 1;137:20-8. doi: 10.1016/j.drugalcdep.2014.01.019. Epub 2014 Feb 12.

49.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002. Epub 2014 Jan 9.

50.

Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

Wiley JL, Marusich JA, Huffman JW.

Life Sci. 2014 Feb 27;97(1):55-63. doi: 10.1016/j.lfs.2013.09.011. Epub 2013 Sep 23. Review.

Supplemental Content

Loading ...
Support Center